Taro Pharmaceutical Industries Past Earnings Performance
Past criteria checks 1/6
Taro Pharmaceutical Industries's earnings have been declining at an average annual rate of -24.8%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 3.3% per year. Taro Pharmaceutical Industries's return on equity is 2.6%, and it has net margins of 7.5%.
Key information
-24.8%
Earnings growth rate
-24.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -3.3% |
| Return on equity | 2.6% |
| Net Margin | 7.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Taro Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 611 | 46 | 198 | 60 |
| 30 Sep 23 | 593 | 33 | 210 | 60 |
| 30 Jun 23 | 575 | 21 | 192 | 57 |
| 31 Mar 23 | 573 | 25 | 198 | 52 |
| 31 Dec 22 | 570 | 46 | 189 | 51 |
| 30 Sep 22 | 569 | 65 | 164 | 52 |
| 30 Jun 22 | 571 | 91 | 146 | 53 |
| 31 Mar 22 | 561 | 58 | 114 | 55 |
| 31 Dec 21 | 566 | 1 | 95 | 56 |
| 30 Sep 21 | 568 | 8 | 93 | 56 |
| 30 Jun 21 | 578 | 29 | 93 | 60 |
| 31 Mar 21 | 549 | -387 | 91 | 60 |
| 31 Dec 20 | 576 | -303 | 98 | 59 |
| 30 Sep 20 | 583 | -268 | 96 | 60 |
| 30 Jun 20 | 601 | -257 | 96 | 59 |
| 31 Mar 20 | 645 | 244 | 93 | 60 |
| 31 Dec 19 | 650 | 248 | 88 | 64 |
| 30 Sep 19 | 678 | 274 | 91 | 64 |
| 30 Jun 19 | 677 | 281 | 86 | 63 |
| 31 Mar 19 | 670 | 282 | 90 | 63 |
| 31 Dec 18 | 665 | 310 | 90 | 63 |
| 30 Sep 18 | 644 | 234 | 88 | 66 |
| 30 Jun 18 | 655 | 224 | 88 | 69 |
| 31 Mar 18 | 662 | 211 | 88 | 70 |
| 31 Dec 17 | 683 | 208 | 87 | 70 |
| 30 Sep 17 | 748 | 330 | 85 | 71 |
| 30 Jun 17 | 807 | 401 | 88 | 67 |
| 31 Mar 17 | 879 | 457 | 86 | 71 |
| 31 Dec 16 | 948 | 489 | 86 | 71 |
| 30 Sep 16 | 986 | 538 | 89 | 71 |
| 30 Jun 16 | 969 | 547 | 92 | 75 |
| 31 Mar 16 | 951 | 541 | 92 | 71 |
| 31 Dec 15 | 930 | 579 | 92 | 75 |
| 30 Sep 15 | 909 | 532 | 91 | 70 |
| 30 Jun 15 | 948 | 542 | 88 | 65 |
| 31 Mar 15 | 863 | 485 | 88 | 66 |
| 31 Dec 14 | 806 | 422 | 92 | 55 |
| 30 Sep 14 | 782 | 395 | 93 | 57 |
| 30 Jun 14 | 736 | 348 | 93 | 58 |
| 31 Mar 14 | 759 | 361 | 92 | 55 |
| 31 Dec 13 | 737 | 321 | 87 | 54 |
| 30 Sep 13 | 709 | 294 | 86 | 51 |
| 30 Jun 13 | 665 | 263 | 87 | 47 |
Quality Earnings: TAL has high quality earnings.
Growing Profit Margin: TAL's current net profit margins (7.5%) are lower than last year (8.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TAL's earnings have declined by 24.8% per year over the past 5 years.
Accelerating Growth: TAL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TAL had negative earnings growth (-0.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: TAL's Return on Equity (2.6%) is considered low.